Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Seres Therapeutics, Inc.
  6. Summary
    MCRB   US81750R1023

SERES THERAPEUTICS, INC.

(MCRB)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/14/2022 01/18/2022 01/19/2022 01/20/2022 01/21/2022 Date
8.04(c) 7.38(c) 7.57(c) 7.62(c) 7.51(c) Last
801 790 938 410 976 158 784 462 864 610 Volume
+3.34% -8.21% +2.57% +0.66% -1.44% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 150 M - -
Net income 2021 -59,3 M - -
Net cash position 2021 169 M - -
P/E ratio 2021 -12,2x
Yield 2021 -
Sales 2022 60,5 M - -
Net income 2022 -183 M - -
Net cash position 2022 151 M - -
P/E ratio 2022 -4,16x
Yield 2022 -
Capitalization 690 M 690 M -
EV / Sales 2021 3,48x
EV / Sales 2022 8,90x
Nbr of Employees 155
Free-Float 91,0%
More Financials
Company
Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company's drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics... 
Read more
More about the company
Ratings of Seres Therapeutics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about SERES THERAPEUTICS, INC.
01/20Seres therapeutics - new england journal of medicine publishes data from ecospor iii ph..
AQ
01/20Canadian Biotech Disruptor Lexston Life Sciences is unlocking the God Molecule (LEXTF, ..
AQ
01/19New England Journal of Medicine Publishes Data from ECOSPOR lll Phase 3 Study Evaluatin..
BU
01/19Seres Therapeutics, Inc. Announces the Publication in the New England Journal of Medici..
CI
01/04Seres Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
BU
2021Seres Announces Preliminary SER-287 Phase 2b ECO-RESET Study Microbiome Data Analysis
BU
2021Seres Therapeutics, Inc. Announces Preliminary SER-287 Phase 2b ECO-RESET Study Microbi..
CI
2021Seres Begins Phase 1b Study of Microbiome Therapeutic in Hematopoietic Stem Cell Transp..
MT
2021Seres Therapeutics Begins Phase 1b Study of Microbiome Therapeutic in Hematopoietic Ste..
MT
2021Seres Therapeutics Announces First Patient Enrolled in Phase 1b Study of SER-155, an In..
BU
2021Seres Therapeutics Announces First Patient Enrolled in Phase 1B Study of SER-155
CI
2021Seres Therapeutics to Present at Piper Sandler 33rd Annual Virtual Healthcare Conferenc..
BU
2021Top Midday Gainers
MT
2021SERES THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition a..
AQ
2021Seres Therapeutics Swings to Profit in Q3 as Revenue Surges, Partners With Bacthera to ..
MT
More news
News in other languages on SERES THERAPEUTICS, INC.
01/19Seres Therapeutics, Inc. annonce la publication dans le New England Journal of Medicine..
2021Seres entame une étude de phase 1b sur le microbiome dans la transplantation de cellule..
2021Seres Therapeutics devient bénéficiaire au troisième trimestre grâce à l'augmentation d..
2021Earnings Flash (MCRB) SERES THERAPEUTICS annonce un chiffre d'affaires de 126,7 million..
2021Lonza JV Bacthera, Seres vont produire conjointement un traitement potentiel contre les..
More news
Analyst Recommendations on SERES THERAPEUTICS, INC.
More recommendations
Chart SERES THERAPEUTICS, INC.
Duration : Period :
Seres Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SERES THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 7,51 $
Average target price 19,13 $
Spread / Average Target 155%
EPS Revisions
Managers and Directors
Eric D. Shaff President, Chief Executive Officer & Director
David A. Arkowitz EVP, Chief Financial & Accounting Officer
Stephen A. Berenson Chairman
Matthew R. Henn Chief Scientific Officer & Executive VP
Barbara McGovern Vice President-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
SERES THERAPEUTICS, INC.-9.84%690
GILEAD SCIENCES, INC.-5.65%85 938
REGENERON PHARMACEUTICALS-2.71%64 971
VERTEX PHARMACEUTICALS3.86%57 990
WUXI APPTEC CO., LTD.-9.18%49 645
BIONTECH SE-42.79%35 624